Prescription investigation for potential adverse drug interactions based on pharmacokinetics of gefitinib and establishment of review rules

CHENG Jun; WANG Long; SI Fuguo; ZHANG Guanjun

doi:10.6039/j.issn.1001-0408.2025.12.16

您当前的位置：

首页 >

文章列表页 >

Prescription investigation for potential adverse drug interactions based on pharmacokinetics of gefitinib and establishment of review rules

更新时间：2025-09-23

- Prescription investigation for potential adverse drug interactions based on pharmacokinetics of gefitinib and establishment of review rules
- ZHONGGUO YAOFANG Vol. 36, Issue 12, Pages: 1511-1514(2025)
- 作者机构：
  
  蚌埠市第三人民医院药学部，安徽蚌埠　233000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.12.16
  CLC： R969.2;R969.3
- Received：06 November 2024，
  
  Revised：2025-03-21，
  
  Accepted：24 March 2025，
  
  Published：30 June 2025
- 稿件说明：
移动端阅览
程军,汪龙,司福国,等.吉非替尼基于药动学的潜在不良药物相互作用处方分析及审方规则建立 [J].中国药房,2025,36(12):1511-1514.

CHENG Jun,WANG Long,SI Fuguo,et al.Prescription investigation for potential adverse drug interactions based on pharmacokinetics of gefitinib and establishment of review rules[J].ZHONGGUO YAOFANG,2025,36(12):1511-1514.
程军,汪龙,司福国,等.吉非替尼基于药动学的潜在不良药物相互作用处方分析及审方规则建立 [J].中国药房,2025,36(12):1511-1514. DOI： 10.6039/j.issn.1001-0408.2025.12.16.

CHENG Jun,WANG Long,SI Fuguo,et al.Prescription investigation for potential adverse drug interactions based on pharmacokinetics of gefitinib and establishment of review rules[J].ZHONGGUO YAOFANG,2025,36(12):1511-1514. DOI： 10.6039/j.issn.1001-0408.2025.12.16.

摘要

目的

分析吉非替尼基于药动学的潜在不良药物相互作用（PK-pADIs），并建立相应审方规则。

方法

通过医院合理用药管理系统抽取我院2022年1月1日－2024年11月30日吉非替尼联合用药的门诊处方，基于Drugs.com

药物相互作用数据库鉴别处方中存在的PK-pADIs，统计具体联用药物及PK-pADIs发生例次，并根据PK-pADIs严重性分级建立审方规则。结果与

结论

共收集到吉非替尼联合用药处方217张，其中28张处方（12.90%）、共计28例患者存在PK-pADIs 29例次，以呼吸内科处方（22张）为主；联用药物包括质子泵抑制剂（13例次）、细胞色素P450 3A4（CYP3A4）强抑制剂（7例次）、H2受体拮抗剂（4例次）、CYP3A4诱导剂（3例次）、CYP2D6底物（2例次），严重性分级分别为严重、中度、严重、中度、中度。根据上述PK-pADIs严重性分级，建立审方规则4项，即吉非替尼与抑酸药物联合使用，予“人工审核”处理；吉非替尼与地塞米松、美托洛尔和CYP3A4强抑制剂联用，予“提醒”处理，并通过提醒框告知医生加强相关指标监测。临床药师需深入呼吸内科等重点临床科室加强有关吉非替尼药物相互作用知识的培训，加强针对长期使用吉非替尼患者的合理用药监测与指导，及时发现并干预PK-pADIs，提高临床用药的合理性、安全性和有效性。

Abstract

OBJECTIVE

To analyze the potential adverse drug interactions based on pharmacokinetics （PK-pADIs） of gefitinib， and establish its corresponding prescription review rules.

METHODS

Outpatient prescriptions of gefitinib combination therapy in our hospital from January 1， 2022 to November 30， 2024 were collected through rational drug software system. PK-pADIs present in the prescriptions were identified based on the Drugs.com

drug interactions database. The specific combination drugs and cases of PK-pADIs were statistically analyzed， and prescription review rules were established according to the severity classification of PK-pADIs.

RESULTS &CONCLUSIONS

A total of 217 prescriptions of gefitinib combination therapy were enrolled. Among them， 28 prescriptions （12.90%）， involving a total of 28 patients， had 29 cases of PK-pADIs， with respiratory medicine prescriptions （22 prescriptions） being the main type. The combination drugs included proton pump inhibitors （13 cases）， strong cytochrome P450 3A4 （CYP3A4） inhibitors （7 cases）， H2 receptor antagonists （4 cases）， CYP3A4 inducers （3 cases）， and CYP2D6 substrates （2 cases）. The severity classifications for these interactions were severe， moderate， severe， moderate and moderate， respectively. Based on the above severity classification of PK-pADIs， four prescription review rules had been established as follows： when gefitinib was combined with acid-suppressing drugs， it should be subject to “manual review”； when gefitinib was combined with dexamethasone， metoprolol， or strong CYP3A4 inhibitors， an “alert” should be triggered， and the physician should be informed via an alert box to strengthen the monitoring of relevant indicators. Clinical pharmacists need to conduct in-depth training on knowledge related to gefitinib drug interactions in key clinical departments such as respiratory medicine. They should strengthen the monitoring and guidance of rational drug use for patients who are on long-term gefitinib therapy， and promptly identify and intervene in PK-pADIs， thereby enhancing the rationality， safety， and effectiveness of clinical drug use.

关键词

Keywords

references

王家乐，邱天羽，崔亚男，等 . 2024 CSCO非小细胞肺癌指南（晚期部分）解读 [J ] . 同济大学学报（医学版）， 2024 ， 45 （ 4 ）： 465 - 470 .

安鹏姣，杨莉萍 . 416例吉非替尼不良反应病例回顾分析 [J ] . 中国医院药学杂志， 2021 ， 41 （ 7 ）： 716 - 723 .

刘治军 . 关于药物相互作用几个问题的思考 [J ] . 药物不良反应杂志， 2019 ， 21 （ 6 ）： 401 - 405 .

GUEDON M ， LE BOZEC A ， BRUGEL M ， et al . Cannabidiol-drug interaction in cancer patients：a retrospective study in a real-life setting [J ] . Br J Clin Pharmacol ， 2023 ， 89 （ 7 ）： 2322 - 2328 .

仲佳，王洁 . 表皮生长因子受体酪氨酸激酶抑制剂药物相互作用概述 [J ] . 中华肿瘤杂志， 2022 ， 44 （ 7 ）： 717 - 724 .

YASUMURO O ， UCHIDA S ， KASHIWAGURA Y ， et al . Changes in gefitinib，erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats [J ] . Xenobiotica ， 2018 ， 48 （ 11 ）： 1106 - 1112 .

TANG W F ， TOMKINSON H ， MASSON E . Effect of sustained elevated gastric pH levels on gefitinib exposure [J ] . Clin Pharmacol Drug Dev ， 2017 ， 6 （ 5 ）： 517 - 523 .

NIEVES SEDANO M ， MANUEL CARO TELLER J ， GARCÍA MUÑOZ C ， et al . Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients [J ] . J BUON ， 2018 ， 23 （ 3 ）： 647 - 653 .

郭子寒，杜琼，叶璇，等 . 合并使用胃酸抑制药可能会降低吉非替尼疗效：基于单个肿瘤中心的回顾性研究 [J ] . 中国药学（英文版）， 2020 ， 29 （ 3 ）： 192 - 198 .

国家卫生健康委员会 . 质子泵抑制剂临床应用指导原则：2020年版 [J ] . 中国实用乡村医生杂志， 2021 ， 28 （ 1 ）： 1 - 9 .

AstraZeneca Pharmaceuticals LP . Iressa：gefitinib tablet，coated [EB/OL ] . [ 2024-10-31 ] . https：//dailymed.nlm.nih.gov/dailymed/drugInfo.cfmsetid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41&audience=consumer https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfmsetid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41&audience=consumer .

SWAISLAND H C ， RANSON M ， SMITH R P ， et al . Pharmacokinetic drug interactions of gefitinib with rifampicin，itraconazole and metoprolol [J ] . Clin Pharmacokinet ， 2005 ， 44 （ 10 ）： 1067 - 1081 .

TAKIMOTO T ， KIJIMA T ， OTANI Y ， et al . Polymorphisms of CYP2D6 gene and gefitinib-induced hepatoto-xicity [J ] . Clin Lung Cancer ， 2013 ， 14 （ 5 ）： 502 - 507 .

PASCUSSI J M ， DROCOURT L ， GERBAL-CHALOIN S ， et al . Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor [J ] . Eur J Biochem ， 2001 ， 268 （ 24 ）： 6346 - 6358 .

CHHUN S ， VERSTUYFT C ， RIZZO-PADOIN N ， et al . Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers [J ] . Br J Clin Pharmacol ， 2009 ， 68 （ 2 ）： 226 - 237 .

HWANG S W ， HAN H S ， LIM K Y ， et al . Drug interaction between complementary herbal medicines and gefitinib [J ] . J Thorac Oncol ， 2008 ， 3 （ 8 ）： 942 - 943 .

Views

952

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰